Image: motorolka, via Shutterstock
Drug company trade body suggests concerns around intellectual property will push R&D investment elsewhere
Plans to change EU rules on drug development would be “extremely damaging” to the bloc’s pharmaceutical industry, according to a trade body.
The European Commission is expected to publish its plans in the coming weeks, with expressed aims that include supporting innovation and ensuring medicines are accessible and affordable.
This article on Research Professional News is only available to Research Professional or Pivot-RP users.
Research Professional users can log in and view the article via this link
Pivot-RP users can log in and view the article via this link.